c-MET

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity..

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM).

MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs).

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.

Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.

Highly potent HGF/c-MET inhibitor; also AT4 antagonist

XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity. XL092 has the potential for kinase-dependent diseases and conditions research.

SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC50s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, Src, and BTK with IC50s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated.

DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.

Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor.

Fosgonimeton is a highly specific small-molecule positive modulator of the HGF/MET (Hepatocyte Growth Factor/Mesenchymal-Epithelial Transition) neurotrophic system.

Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity.

CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.

Gemnelatinib is a tyrosine kinase inhibitor (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer.

ABN401 is a highly potent and selective ATP-competitive c-MET inhibitor with an IC50 value of 10 nM. ABN401 has cytotoxic activity against MET-addicted cancer cells. ABN401 can inhibit c-MET phosphorylation in tumor tissues. ABN401 can be used for researching anticancer.

BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma.

Capmatinib (INC280; INCB28060) dihydrochloride hydrate is an effective, orally active, selective, ATP-competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit the phosphorylation of c-MET and downstream effectors such as ERK1/2, AKT, FAK, GAB1 and STAT3/5 in the c-MET pathway. Capmatinib dihydrochloride hydrate effectively inhibits proliferation and migration of c-Met-dependent tumor cells and induces apoptosis. It exhibits anti-tumor activity in mouse models of cancer. Capmatinib dihydrochloride hydrate is mainly metabolized by CYP3A4 and aldehyde oxidase.

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody of the IgG4 type. Emibetuzumab has high neutralizing and internalizing activity, effectively inhibiting the activation and tumor growth of both HGF-dependent and independent MET pathways. Emibetuzumab can be used for cancer research.

Ficlatuzumab is a monoclonal antibody (McAb) that targets human hepatocyte growth factor (HGF). Ficlatuzumab can block the activation of the HGF/c-Met signaling pathway, inhibiting c-Met receptor-mediated cancer cell proliferation, migration and invasion.

Mefatinib free base is an effective tyrosine kinase inhibitor with anti-tumor activity.

Mefatinib is an effective tyrosine kinase inhibitor with anti-tumor activity.